Aprea Therapeutics Secures $3.1M in Private Placement

Aprea Therapeutics ( (APRE) ) just unveiled an update.

On December 8, 2025, Aprea Therapeutics entered into a securities purchase agreement with accredited investors and company insiders to issue and sell 2,623,023 shares of common stock and warrants in a private placement, expected to close on December 10, 2025, for approximately $3.1 million. This financing is anticipated to extend Aprea’s cash runway into Q1 2027, supporting its clinical programs and general corporate purposes, with Maxim Group LLC acting as the sole placement agent.

The most recent analyst rating on (APRE) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.

Spark’s Take on APRE Stock

According to Spark, TipRanks’ AI Analyst, APRE is a Underperform.

Aprea Therapeutics receives a low overall score due to significant financial challenges, including consistent losses and lack of revenue generation. The company’s strong balance sheet is a positive but is offset by negative cash flows and a reliance on external financing. Technical indicators suggest a bearish trend, and the valuation is unattractive due to a negative P/E ratio and no dividend yield.

To see Spark’s full report on APRE stock, click here.

More about Aprea Therapeutics

Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments that target specific cancer cell vulnerabilities while minimizing harm to healthy cells. The company is working on therapies for various cancer types, including ovarian, endometrial, colorectal, prostate, and breast cancers, with lead programs like APR-1051 and ATRN-119 in clinical development for solid tumor indications.

Average Trading Volume: 85,645

Technical Sentiment Signal: Sell

Current Market Cap: $6.69M

See more insights into APRE stock on TipRanks’ Stock Analysis page.